Effects of sulindac on sporadic colorectal adenomatous polyps

Gut

Volumn 40, Issue 3, 1997, Pages 344-349

  Matsuhashi, N ^a   Nakajima, A ^a   Fukushima, Y ^a   Yazaki, Y ^a   Oka, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

colorectal cancer; familial adenomatous polyposis; NSAID; sporadic colorectal adenomatous polyp; sulindac

Indexed keywords

SULINDAC;

ADENOMA; ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; COLONOSCOPY; COLORECTAL DISEASE; FEMALE; HUMAN; MALE; POLYPOSIS; PRIORITY JOURNAL;

EID: 0030992045     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.3.344     Document Type: Article

References (57)

1. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-7.
2. Gonzaga RAF, Lima FR, Carneiro S, Maciel J, Amarante Jr M. Sulindac treatment for familial polyposis coli. Lancet 1985; i: 751.
3. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac polyposis of the colon. Am J Surg 1989; 157: 175-9.
4. Friend W. Sulindac suppression of colorectal polyps in Gardner's syndrome. Am Fam Phys 1990; 41: 891-4.
5. Chameau J, D'Aubigny N, Burtin P, Person B, Boyer J. Micropolypes rectaux apres colectomie totale pour polypose familiale: efficacite du sulindac. Gastroenterol Clin Biol 1990; 14: 153-7.
6. Labayle D, Fischre D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-9.
7. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effect of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-4.
8. Giardiello FM, Hamilton SR, Krush AJ, Hylind LM, Celano P, Booker SV, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-6.
9. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-9.
10. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration, Int J Colorectal Dis 1993; 8: 13-7.
11. Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R, Anastasi A, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-6.
12. Winde G, Scmid KW, Schlegel W, Fischer R, Osswald H, Bunte H. Complete reversion and prevention of rectal adenomas in colectomizcd patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995; 38: 813-30.
13. Hiraka K, Itoh H, Ohsato K. Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis. Dis Colon Rectum 1994; 37: 943-6.
14. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RF. NSAIDs effect on sporadic colon polyps. Am J Gastroenterol 1993; 88: 1652-6.
15. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995; 108: 1083-7.
16. DuBois RN. Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. Gastroenterology 1995; 108: 1310-4.
17. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
18. Vasen HFA, Mecklin JP, Khan PM, Lynch HT. Hereditary non-polyposis colorectal cancer. Lancet 1991; 338: 877.
19. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol 1991; 138: 807-13.
20. Powles TJ, Clark SA, Easty DM, Easty GC, Neville AM. The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcemia in rats with Walker tumour and is possible application to human breast cancer. Br J Cancer 1973; 28: 316-21.
21. Humes JL, Strausseer HR. Prostaglandins and cyclic nucleotides in Moloney sarcoma tumors. Prostaglandins 1974; 5: 183-96.
22. Strausser HR, Humes JL. Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in BALB/c mice. Cancer 1975; 15: 724-30.
23. Hial V, Horakova Z, Shaff RE, Beaven MA. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol 1976; 37: 367-76.
24. Hial V, De Mello MC, Schaff RE, Horakova Z, Beaven MA. Anti-proliferative activity of anti-inflammatory drugs in two mammalian cell culture lines. J Pharmacol Exp Ther 1977; 202: 446-54.
25. Lynch NR, Castes M, Astoin M, Salomon JC. Mechanism of inhibition of tumor growth by aspirin and indomethacin. Br J Cancer Inst 1979; 62: 117-21.
26. Lynch NR, Salomon JC. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst 1979; 62: 117-21.
27. Bennett A, Houghton J, Leaper DJ, Stanford IF. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins 1979; 17: 179-91.
28. Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol 1980; 15: 85-90.
29. Al Saleem T, Ali ZS, Qassab M. Skin cancers in xeroderma pigmentosum: response to indomethacin and steroids. Lancet 1980; ii: 264-5.
30. Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981; 107: 658-63.
31. Parker AL, Kadakia SC, Maccini DM, Cassaday MA, Angueira CE. Disappearance of polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol 1993; 88: 93-4.
32. Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R. Reduced risk of large bowel adenomas among aspirin users. J Natl Cancer Inst 1993; 85: 912-6.
33. Logan RFA, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993; 307: 285-9.
34. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
35. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
36. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal antiinflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 85: 355-8.
37. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
38. Waddell WR. The effect of sulindac on colon polyps: circumvention of a transformed phenotype-a hypothesis. J Surg Oncol 1994; 55: 52-5.
39. Shiff SJ, Qiao L, Tsai L, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491-503.
40. Waddell WR, Miesfeld RL. Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac. J Surg Oncol 1995; 58: 252-6.
41. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-8.
42. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RKS. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 1995; 345: 855-6.
43. Goldberg Y, Dynlacht BD, Rigas B, Shiff SJ. Sulindac and sulindac sulfide alter the levels of pRb and p53 and the cyclin dependent kinase inhibitor p21 in HT-29 colon cancer cells. Gastroenterology 1995; 108: A475.
44. Yukawa M, Fujimori T, Maeda S, Tabuchi M, Nagasako K. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut 1994; 35: 1258-61.
45. Prioleau JP, Schnitt SJ. p53 antigen loss in stored paraffin slides. N Engl J Med 1995; 332: 1521-2.
46. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340-6.
47. Moorghen M, Ince P, Finney LJ, Sunter PJ, Appleton DR, Watson AJ. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 1988; 156: 341-7.
48. Northway MG, Scobey MW, Gassidy KT, Geisinger KR. Piroxicam decreases post irradiation colonic neoplasia in the rat. Cancer 1990; 66: 2300-5.
49. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990; 50: 2562-8.
50. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha- difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination, Cancer Res 1991; 51: 4528-34.
51. Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991; 126: 1094-6.
52. Craven PA, DeRubertis FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 1992; 13: 541-6.
53. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992; 13: 1019-23.
54. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effects of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-7.
55. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72.
56. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994; 107: 854-7.
57. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged Chemoprevention. Cancer 1995; 75: 936-8.